ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4912ometendo-4912Research ArticleСтатьиArticlesКлинический случай успешного применения моксонидина у пациентки с постменопаузальным метаболическим синдромомKlinicheskiy sluchay uspeshnogo primeneniya moksonidina u patsientki s postmenopauzal'nym metabolicheskim sindromomPodzolkovV I-GladyshevaE A-20071503200741№1 (2007)3740Copyright © Podzolkov V.I., Gladysheva E.A., 20072007Podzolkov V.I., Gladysheva E.A.Podzolkov V.I., Gladysheva E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4912ReferencesАничков Д.А., Шостак Н.А., Журавлева А.Д. Менопауза и сердечно-сосудистый риск. Рац. кардиол. фармакотер. 2005; 1(1):37-42.Аничков Д.А., Шостак Н.А., Журавлева А.Д. Менопауза и сердечно-сосудистый риск. Рац. кардиол. фармакотер. 2005; 1(1):37-42.Мычка В.Б. Артериальная гипертония и ожирение. Consilium provisorum 2002; 5:18-21.Мычка В.Б. Артериальная гипертония и ожирение. Consilium provisorum 2002; 5:18-21.Мычка В.Б., Горностаев В.В., Богиева Р.М., Чазова И.Е. Артериальная гипертония у больных сахарным диабетом 2 типа и метаболическим синдромом. Сonsilium Medicum. Приложение Артериальная гипертония. 2001; 1:25-30.Мычка В.Б., Горностаев В.В., Богиева Р.М., Чазова И.Е. Артериальная гипертония у больных сахарным диабетом 2 типа и метаболическим синдромом. Сonsilium Medicum. Приложение Артериальная гипертония. 2001; 1:25-30.Оганов Р.Г., Александров А.А. Гиперинсулиненмия и артериальная гипертония:возвращаясь к выводам United Kingdom Prospective Diabetes Study. Русский мед. жур. 2002; 10(11):486-491.Оганов Р.Г., Александров А.А. Гиперинсулиненмия и артериальная гипертония:возвращаясь к выводам United Kingdom Prospective Diabetes Study. Русский мед. жур. 2002; 10(11):486-491.Проект Второго пересмотра рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2004; 3(3). Ч. 1.Проект Второго пересмотра рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардиоваскулярная терапия и профилактика. 2004; 3(3). Ч. 1.Подзолков В.И., Брагина А.Е., Маколкин В.И. Патогенетическая роль моксонидина при лечении артериальной гипертензии у женщин в перименопаузе. Кардиология 2002; 11:32-35.Подзолков В.И., Брагина А.Е., Маколкин В.И. Патогенетическая роль моксонидина при лечении артериальной гипертензии у женщин в перименопаузе. Кардиология 2002; 11:32-35.Чазова И.Е., Мычка В.Б. Метаболический синдром. М.:Медиа; 2004:168.Чазова И.Е., Мычка В.Б. Метаболический синдром. М.:Медиа; 2004:168.Чазова И.Е., Мычка В.Б. Метаболический синдром и артериальная гипертония. Артериальная гипертензия 2002; 8(1).Чазова И.Е., Мычка В.Б. Метаболический синдром и артериальная гипертония. Артериальная гипертензия 2002; 8(1).Ames R.P., Hill P.H. Antihypertensive therapy and risk of coronary heart disease.J Cardiovasc Pharmacol. 1982;4 (Suppl.2): S206-16.Ames R.P., Hill P.H. Antihypertensive therapy and risk of coronary heart disease.J Cardiovasc Pharmacol. 1982;4 (Suppl.2): S206-16.Carr M.C. The emergence of metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88:2404-11.Carr M.C. The emergence of metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88:2404-11.Edmunds E., Lip G.Y. Cardiovascular risk in women:the cardiologist,s perspective. QJM. 2000; 93(3):135-45.Edmunds E., Lip G.Y. Cardiovascular risk in women:the cardiologist,s perspective. QJM. 2000; 93(3):135-45.Mercuro G., Zoncu S., Cherchi A., Rosano G.M. Can menopause be considered an independent risk factor for cardiovascular disease? Ital Heart J. 2001; 2(10):719-27.Mercuro G., Zoncu S., Cherchi A., Rosano G.M. Can menopause be considered an independent risk factor for cardiovascular disease? Ital Heart J. 2001; 2(10):719-27.Elisaf M.S., Petris C., Bairaktari E., Karabina S.A., Tzallas C., Tselepis A., Siamopoulos K.C. The effect of moxonidine on plasma lipid profile and on LDL subclass distribution. J Human Hypertension. 1999; 13:781-785.Elisaf M.S., Petris C., Bairaktari E., Karabina S.A., Tzallas C., Tselepis A., Siamopoulos K.C. The effect of moxonidine on plasma lipid profile and on LDL subclass distribution. J Human Hypertension. 1999; 13:781-785.Ernsberger P. Pharmacology of moxonidine: An I1-imidasoline receptor ago nist. J Cardiovascular Pharmacology. 2000; 35 Suppl. 4:27-S41.Ernsberger P. Pharmacology of moxonidine: An I1-imidasoline receptor ago nist. J Cardiovascular Pharmacology. 2000; 35 Suppl. 4:27-S41.European Guidelines on cardiovascular disease prevention on clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and invited experts). Eur Heart J. 2003; 24:1601-10.European Guidelines on cardiovascular disease prevention on clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and invited experts). Eur Heart J. 2003; 24:1601-10.Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults:Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults:Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.Grimm R.H., Grandits G.A., Culter J.A., Stewart A.L. et al. Relationship of quality of life measures to long-term lifestyle and drug treatment in the treatment of mild hypertension study (TOMHS). Arch Intern Med. 1997; 157:638-48.Grimm R.H., Grandits G.A., Culter J.A., Stewart A.L. et al. Relationship of quality of life measures to long-term lifestyle and drug treatment in the treatment of mild hypertension study (TOMHS). Arch Intern Med. 1997; 157:638-48.Houston M.C. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J. 1988; 115(3):640-56.Houston M.C. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J. 1988; 115(3):640-56.Julius S., Guabrandsson T., Jamerson K., Shahab S.T., Andersson O. The hemodinamic link between insulin resistance and hypertension. J Hypertens. 1991; 9:983-6Julius S., Guabrandsson T., Jamerson K., Shahab S.T., Andersson O. The hemodinamic link between insulin resistance and hypertension. J Hypertens. 1991; 9:983-6Kirch W., Hutt H.J., Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet. 1988; 15:245-253.Kirch W., Hutt H.J., Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet. 1988; 15:245-253.Krespi P.G., Makris T.K., Hatzizacharias A.N., Triposkiadis P., Stoical C., Kiribati D., Votteas V., Kyriakidis M. Moxonidine effect on microalbuminuria, trombomodulin and plasminogen activator ingibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther. 1998; 12(5):463-467.Krespi P.G., Makris T.K., Hatzizacharias A.N., Triposkiadis P., Stoical C., Kiribati D., Votteas V., Kyriakidis M. Moxonidine effect on microalbuminuria, trombomodulin and plasminogen activator ingibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther. 1998; 12(5):463-467.Spenser C.P., Godsland I.F., Stevenson J.C. Is there a menopausal metabolic syndrome. Gynecol Endocrinol 1997; 11:341-55.Spenser C.P., Godsland I.F., Stevenson J.C. Is there a menopausal metabolic syndrome. Gynecol Endocrinol 1997; 11:341-55.Waters K., Ashford J., Jager B., Wonnacott S., Verboome C.N. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension. results of the TOPIC (Trial Of Physiotens In Combination) Study. J CLin Basic Cardiol. 1999; 2:219-224.Waters K., Ashford J., Jager B., Wonnacott S., Verboome C.N. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension. results of the TOPIC (Trial Of Physiotens In Combination) Study. J CLin Basic Cardiol. 1999; 2:219-224.Witteman J.C., Grobbe D.E., Kok E.J. et al. Increased risk of atherosclerosis in women after the menopause. BMJ 1989; 298:642-4.Witteman J.C., Grobbe D.E., Kok E.J. et al. Increased risk of atherosclerosis in women after the menopause. BMJ 1989; 298:642-4.
The authors declare that there are no conflicts of interest present.